摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-戊炔-1-基环己烷 | 5963-75-7

中文名称
4-戊炔-1-基环己烷
中文别名
——
英文名称
pent-4-yn-1-ylcyclohexane
英文别名
1-cyclohexyl-4-pentyne;5-Cyclohexyl-1-pentyne;pent-4-ynylcyclohexane
4-戊炔-1-基环己烷化学式
CAS
5963-75-7
化学式
C11H18
mdl
MFCD00045517
分子量
150.264
InChiKey
RZBWOCFHDCCGNK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.818
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-戊炔-1-基环己烷(R)-(S)-josiphos四甲基乙二胺 、 zinc-copper couple 、 二苯基硅烷溶剂黄146copper(l) chloridesodium t-butanolate 作用下, 以 四氢呋喃乙二醇二甲醚乙醚乙醇 为溶剂, 反应 6.75h, 生成 (R)-3-(3-cyclohexylpropyl)cyclobut-1-en-1-yl diphenyl phosphate
    参考文献:
    名称:
    通过催化共轭加成/俘获策略对3-取代的环戊二烯进行对映选择性合成。
    摘要:
    已经开发了铜催化的串联方法以产生手性环丁烯衍生物。它基于一锅法中环丁烯酮的对映选择性共轭添加或还原,以及用氯磷酸盐顺序捕集。这些磷酸盐在弱酸性条件下稳定,在Negishi偶联反应中可作为良好的亲电子试剂。
    DOI:
    10.1002/anie.201913825
  • 作为产物:
    描述:
    3-环已基-1-丙醇硫酸氢溴酸 作用下, 以 二甲基亚砜 为溶剂, 反应 12.0h, 生成 4-戊炔-1-基环己烷
    参考文献:
    名称:
    Nucleosides and nucleotides. 107. 2-(Cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects
    摘要:
    Adenosine receptor-binding profiles in rat brain tissues and antihypertensive effects in spontaneously hypertensive rats (SHR) of a series of 2-(cycloalkylalkynyl)adenosines (2-CAAs) and their congeners are described. The structure-activity relationship of this series of compounds is discussed, focusing on the length of the alkynyl side chain and bulkiness of the terminal cycloalkyl substituents in terms of binding activity and cardiovascular effects. All the 2-CAAs had a preferential affinity for A2 receptors. Of these derivatives, 2-(3-cyclopentyl-1-propyn-1-yl)adenosine (10b) exhibited the most selective affinity for A2 receptors (K(i) ratio: A1/A2 = 70) on the basis of receptor binding. In the C-2 binding region of adenosine, compounds often have potent and/or selective A2 activity from introduction of an acetylenic group at the C-2 position followed by one methylene residue further followed by a hydrophobic substituent such as a cycloalkyl ring at the terminal position of the alkynyl side chain. Intravenous injection of 10b up to 100-mu-g/kg had a potent hypotensive effect without a marked decrease in heart rate in anesthetized SHR. Compounds 10j-s, with a hydroxyl group in the C-3" position of the alkynyl side chain, had a potent affinity for both A1 and A2 receptors, but they were not highly selective for A2 receptors. These compounds caused a marked bradycardia upon intravenous administration in anesthetized SHR. Oral administration of 10b (0.1-1 mg/kg) had a potent and long-lasting antihypertensive effect in conscious SHR.
    DOI:
    10.1021/jm00090a017
点击查看最新优质反应信息

文献信息

  • Thiophenol-Mediated 1,5-Hydrogen Atom Abstraction: Easy Access to Mono- and Bicyclic Compounds
    作者:Florent Beaufils、Fabrice Dénès、Barbara Becattini、Philippe Renaud、Kurt Schenk
    DOI:10.1002/adsc.200505211
    日期:2005.10
    method for cyclization of alkynes is described. The reaction cascade involves the intermolecular addition of a phenylthiyl radical to a terminal triple bond generating an alkenyl radical, followed by a 1,5-hydrogen atom transfer and a 5-exo-trig radical cyclization. This very efficient tin-free procedure allows one to prepare highly functionalized cyclopentane derivatives as well as fused bicyclic and
    描述了硫代苯酚介导的炔烃环化方法。反应级联反应涉及在分子间将苯基噻吩基分子间加成到末端三键上,从而产生烯基基团,然后进行1,5-氢原子转移和5- exo- trig自由基环化。这种非常有效的无锡程序使人们可以从容易获得的前体制备高度官能化的环戊烷衍生物以及稠合的双环和螺环化合物。在该环化过程中,将苯硫基部分掺入最终的环化产物中。这种功能化对于产品的进一步转化特别有吸引力。
  • Amino alcohol derivatives
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20030236297A1
    公开(公告)日:2003-12-25
    Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives: 1 wherein R 1 and R 2 are a hydrogen atom, an amino protecting group; R 3 is a hydrogen atom, a hydroxy protecting group; R 4 is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C 1 -C 10 alkylene group, a C 1 -C 10 alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R 5 is an aryl group; R 6 and R 7 are a hydrogen atom, a group selected from substituent group a; with the proviso when R 5 is a hydrogen atom, Y is not a single bond or a straight chain C 1 -C 10 alkylene group.
    式(I)的化合物表现出优异的免疫抑制活性,其药理学上可接受的盐,酯或其他衍生物:其中R1和R2是氢原子,氨基保护基;R3是氢原子,羟基保护基;R4是较低的烷基基团;n是1到6之间的整数;X是乙烯基团;Y是C1-C10烷基基团,带有1到3个从取代基a和b中选择的取代基的C1-C10烷基基团;R5是芳基基团;R6和R7是氢原子,从取代基a中选择的基团;但是当R5是氢原子时,Y不是单键或直链的C1-C10烷基基团。
  • 1-substituted-2, 4-diamino-6, 6-dialkyl-1, 6-dihydro-1, 3, 5-triazines
    申请人:FMC Corporation
    公开号:US05565451A1
    公开(公告)日:1996-10-15
    An insecticidal composition comprising, in admixture with an agriculturally acceptable carrier, an insecticidally effective amount of a 1,3,5-triazine compound of the formula ##STR1## where n is 0-4; and R is lower alkyl, or ##STR2## wherein V, W, X, Y, and Z are as defined herein; and methods of using this composition.
    一种杀虫组合物,与农业可接受的载体混合,包含有效的杀虫剂量的1,3,5-三嗪化合物,其化学式为##STR1##其中n为0-4;R为较低烷基,或##STR2##其中V、W、X、Y和Z如本文所定义;以及使用该组合物的方法。
  • Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
    申请人:Nishi Takahide
    公开号:US20050043386A1
    公开(公告)日:2005-02-24
    Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.
    具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物,其药理学上可接受的盐和药理学上可接受的酯,以及包含这些化合物的制药组合物,其中化合物具有以下式子:其中R1和R2各代表氢,或氨基保护基;R3代表氢,或羟基保护基;R4代表较低的烷基;n为1至6;X代表氧或氮,未取代或取代为较低的烷基;Y代表乙烯;Z代表C1-C10烷基;R5代表芳基;R6和R7各代表氢;但是当R5代表氢时,Z代表除单键或直链C1-C10烷基组以外的一种基团。
  • Heterocyclic Compounds with Affinity to Muscarinic Receptors
    申请人:Stoit Axel
    公开号:US20090018160A1
    公开(公告)日:2009-01-15
    The present invention relates to heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof wherein the heterocycle comprises two double bonds which may be present at several positions, and which are represented by the dashed lines (---); the heterocycle contains two heteroatoms, W is N or NH; Y is CH, O or NH, wherein if Y is O, X 1 is CH and X 2 is C-Z-R2 or C—R3, wherein Z is NH, O, or S; and if Y is CH or NH, one of X 1 and X 2 is CH or N, wherein if X 1 is CH or N, X 2 is C-Z-R2 or C—R3, and if X 2 is CH or N, X 1 is C-Z-R2 or C—R3, wherein Z is NH or S; R1 is chosen from structures (a), (b) and (c): R2 is chosen from (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, oxo, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and R3 is chosen from (C 4 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and optionally, when R2 is an unbranched (C 2 -C 8 )alkyl, R2 links to formula (Ia) or a pharmaceutically acceptable salt, a solvate or hydrate thereof, through the X 1 a or X 2 a of formula (Ia), wherein if X 1 is CH or N, X 1 a is CH or N and X 2 a is C-Za-, or if X 1 is C-Z-R2, X 1 a is C-Za- and X 2 a is CH or N, wherein X 1 a or X 2 a having Za links to R2; and the symbols Wa, Ya and Za and the substituent R1 a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1 a representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I). The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.
    本发明涉及公式(I)的杂环化合物或其药学上可接受的盐、溶剂或水合物,其中杂环包含两个双键,可以存在于多个位置,并由虚线(---)表示;杂环含有两个杂原子,W为N或NH;Y为CH,O或NH,其中如果Y为O,X1为CH,X2为C-Z-R2或C—R3,其中Z为NH,O或S;如果Y为CH或NH,X1和X2中的一个为CH或N,其中如果X1为CH或N,X2为C-Z-R2或C—R3,如果X2为CH或N,则X1为C-Z-R2或C—R3,其中Z为NH或S;R1选择自结构(a)、(b)和(c):R2选择自(C1-C10)烷基,(C2-C10)烯基和(C2-C10)炔基,可选地独立取代一个或多个取代基,所选的取代基选择自卤素,羟基,氰基,氧代基,(C1-C6)烷氧基,(C1-C6)烷基硫基,(C1-C6)烯基氧基,(C1-C6)烯基硫基,(C1-C4)烷氧基(C1-C4)烷氧基,(C5-C7)环烷基,一种5-成员不饱和杂环(可选地取代卤素),苯基,苯氧基和苯硫基,其中苯基可选地取代卤素;R3选择自(C4-C10)烷基,(C2-C10)烯基和(C2-C10)炔基,可选地独立取代一个或多个取代基,所选的取代基选择自卤素,羟基,氰基,(C1-C6)烷氧基,(C1-C6)烷基硫基,(C1-C6)烯基氧基,(C1-C6)烯基硫基,(C1-C4)烷氧基(C1-C4)烷氧基,(C5-C7)环烷基,一种5-成员不饱和杂环,可选地取代卤素,苯基,苯氧基和苯硫基,其中苯基可选地取代卤素;可选地,当R2为直链(C2-C8)烷基时,R2通过公式(Ia)或其药学上可接受的盐、溶剂或水合物与公式(I)连接,其中如果X1为CH或N,X1a为CH或N,X2a为C-Za-,或如果X1为C-Z-R2,X1a为C-Za-,X2a为CH或N,其中X1a或X2a具有Za连接到R2;符号Wa,Ya和Za和取代基R1a具有与先前定义的符号W,Y和Z和取代基R1相同的含义,并且不能独立选择,每个符号Wa,Ya和Za和取代基R1分别表示与公式(I)结构的其他部分中的符号W,Y和Z和取代基R1相同的符号和取代基。本发明的化合物具有亲和力,可以用于治疗、缓解或预防毒蕈碱受体介导的疾病和症状。
查看更多